The proportion of CD34+ CD38low or neg myeloblasts, but not side population frequency, predicts initial response to induction therapy in patients with newly diagnosed acute myeloid leukemia

Leukemia

Volumn 27, Issue 3, 2013, Pages 728-731

  Roshal, M ^a   Chien, S ^b   Othus, M ^c   Wood, B L ^d   Fang, M ^c,d   Appelbaum, F R ^b,c   Estey, E H ^b,c   Papayannopoulou, T ^b   Becker, P S ^b  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c USA   (United States)

^d SEATTLE CANCER CARE ALLIANCE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; CANCER PROGNOSIS; CD34+ CD38 MYELOBLAST; CLINICAL ARTICLE; CYTOGENETICS; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; INDUCTION CHEMOTHERAPY; LETTER; MYELOBLAST; PRIORITY JOURNAL; SIDE POPULATION CELL;

ADULT; AGED; AGED, 80 AND OVER; ANIMALS; ANTIGENS, CD34; ANTIGENS, CD38; BLAST CRISIS; CASE-CONTROL STUDIES; COMBINED MODALITY THERAPY; CYTOGENETIC ANALYSIS; FEMALE; FLOW CYTOMETRY; GRANULOCYTE PRECURSOR CELLS; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MICE; MICE, INBRED NOD; MICE, SCID; MIDDLE AGED; PROGNOSIS; RECEPTORS, INTERLEUKIN-2; REMISSION INDUCTION; YOUNG ADULT;

EID: 84875222844     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2012.217     Document Type: Letter

References (15)

1. Bhatia M, Wang JC, Kapp U, Bonnet D, Dick JE. Purification of primitive human hematopoietic cells capable of repopulating immune-deficient mice. Proc Natl Acad Sci USA 1997; 94: 5320-5325.
2. Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 1997; 3: 730-737.
3. van Rhenen A, Feller N, Kelder A, Westra AH, Rombouts E, Zweegman S et al. High stem cell frequency in acute myeloid leukemia at diagnosis predicts high minimal residual disease and poor survival. Clin Cancer Res 2005; 11: 6520-6527.
4. Witte KE, Ahlers J, Schafer I, Andre M, Kerst G, Scheel-Walter HG et al. High proportion of leukemic stem cells at diagnosis is correlated with unfavorable prognosis in childhood acute myeloid leukemia. Pediatr Hematol Oncol 2011; 28: 91-99.
5. Zhou S, Schuetz JD, Bunting KD, Colapietro AM, Sampath J, Morris JJ et al. The ABC transporter Bcrp1/ABCG2 is expressed in a wide variety of stem cells and is a molecular determinant of the side-population phenotype. Nat Med 2001; 7: 1028-1034.
6. Goodell MA, Brose K, Paradis G, Conner AS, Mulligan RC. Isolation and functional properties of murine hematopoietic stem cells that are replicating in vivo. J Exp Med 1996; 183: 1797-1806.
7. Challen GA, Little MH. A side order of stem cells: the SP phenotype. Stem Cells 2006; 24: 3-12.
8. Ho MM, Ng AV, Lam S, Hung JY. Side population in human lung cancer cell lines and tumors is enriched with stem-like cancer cells. Cancer Res 2007; 67: 4827-4833.
9. Christgen M, Geffers R, Ballmaier M, Christgen H, Poczkaj J, Krech T et al. Down-regulation of the fetal stem cell factor SOX17 by H33342: a mechanism responsible for differential gene expression in breast cancer side population cells. J Biol Chem 2010; 285: 6412-6418.
10. Oates JE, Grey BR, Addla SK, Samuel JD, Hart CA, Ramani VA et al. Hoechst 33342 side population identification is a conserved and unified mechanism in urological cancers. Stem Cells Dev 2009; 18: 1515-1521.
11. Feuring-Buske M, Hogge DE. Hoechst 33342 efflux identifies a subpopulation of cytogenetically normal CD34\+CD38-progenitor cells from patients with acute myeloid leukemia. Blood 2001; 97: 3882-3889.
12. Wulf GG, Wang RY, Kuehnle I, Weidner D, Marini F, Brenner MK et al. A leukemic stem cell with intrinsic drug efflux capacity in acute myeloid leukemia. Blood 2001; 98: 1166-1173.
13. Moshaver B, van Rhenen A, Kelder A, van der Pol M, Terwijn M, Bachas C et al. Identification of a small subpopulation of candidate leukemia-initiating cells in the side population of patients with acute myeloid leukemia. Stem Cells 2008; 26: 3059-3067.
14. Essers MA, Trumpp A. Targeting leukemic stem cells by breaking their dormancy. Mol Oncol 2010; 4: 443-450.
15. Gentles AJ, Plevritis SK, Majeti R, Alizadeh AA. Association of a leukemic stem cell gene expression signature with clinical outcomes in acute myeloid leukemia. JAMA 2010; 304: 2706-2715.